Key result
Aspirin remains the compelling standard for secondary prevention of platelet-dependent vascular occlusion, while glycoprotein IIb/IIIa antagonists are emerging as promising competitors.
Aspirin remains the compelling standard for secondary prevention of vascular occlusion, while glycoprotein IIb/IIIa antagonists emerge as promising competitors requiring safe delivery methods.
No takes yet. Share an insight, caveat, or question.
Aspirin should remain standard for secondary prevention; leaves open glycoprotein IIb/IIIa antagonists as competitors pending prospective trials.
Fitzgerald et al. (1994) conducted a review in Secondary prevention of platelet dependent vascular occlusion. Antiplatelet drugs (aspirin, glycoprotein IIb/IIIa antagonists) was evaluated. Aspirin remains the compelling standard for secondary prevention of platelet-dependent vascular occlusion, while glycoprotein IIb/IIIa antagonists are emerging as promising competitors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: